4//SEC Filing
Vanda Pharmaceuticals Inc. 4
Accession 0001209191-17-002226
$VNDACIK 0001347178operating
Filed
Jan 4, 7:00 PM ET
Accepted
Jan 5, 5:13 PM ET
Size
22.2 KB
Accession
0001209191-17-002226
Insider Transaction Report
Form 4
Baroldi Paolo
SVP & Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2017-01-03+5,000→ 58,165 total - Exercise/Conversion
Common Stock
2017-01-03+7,500→ 70,665 total - Exercise/Conversion
Restricted Stock Unit
2017-01-03+12,500→ 0 total→ Common Stock (12,500 underlying) - Exercise/Conversion
Restricted Stock Unit
2017-01-03+7,500→ 22,500 total→ Common Stock (7,500 underlying) - Exercise/Conversion
Common Stock
2017-01-03+12,500→ 53,165 total - Exercise/Conversion
Common Stock
2017-01-03+5,000→ 63,165 total - Exercise/Conversion
Restricted Stock Unit
2017-01-03+5,000→ 5,000 total→ Common Stock (5,000 underlying) - Sale
Common Stock
2017-01-03$15.51/sh+16,300$252,776→ 54,365 total - Exercise/Conversion
Restricted Stock Unit
2017-01-03+5,000→ 10,000 total→ Common Stock (5,000 underlying)
Footnotes (8)
- [F1]Each Restricted Stock Unit ("RSU") represents a contingent right to receive a share of the Issuer's common stock.
- [F2]Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs as reflected in this Form 4. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.30 to $15.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
- [F4]The RSUs shall vest in four (4) equal annual installments beginning January 1, 2014, provided Reporting Person has remained in continuous service with the Issuer on each applicable vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest.
- [F5]Not Applicable.
- [F6]The RSUs shall vest in four (4) equal annual installments beginning January 1, 2015, provided Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest.
- [F7]The RSUs shall vest in four (4) equal annual installments beginning January 1, 2016, provided Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest.
- [F8]The RSUs shall vest in four (4) equal annual installments beginning January 1, 2017, provided Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest.
Documents
Issuer
Vanda Pharmaceuticals Inc.
CIK 0001347178
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001347178
Filing Metadata
- Form type
- 4
- Filed
- Jan 4, 7:00 PM ET
- Accepted
- Jan 5, 5:13 PM ET
- Size
- 22.2 KB